Goldman Sachs sees adjuvant oral SERDs becoming a roughly $27bn peak-sales class, with Lilly’s imlunestrant underappreciated

Overview

Goldman Sachs examines whether next-generation oral SERDs can create a major commercial category in adjuvant HR-positive, HER2-negative early breast cancer. Its market model favors a large long-duration treatment opportunity, with clinical readouts, regulatory labels, uptake curves and tolerability set to determine how value is distributed among Roche, AstraZeneca, Lilly and Menarini.

Core views

Goldman Sachs argues that oral selective estrogen receptor degraders could become a multi-billion-dollar category by addressing limitations of generic endocrine therapy, including resistance associated with ESR1 mutations, tolerability issues and the inconvenience of older injectable SERDs. HR-positive, HER2-negative disease represents about 70% of new breast-cancer cases and roughly 225,000 US cases annually. Although oral SERDs are currently approved principally in metastatic ESR1-mutated disease, the report sees the substantially larger opportunity in adjuvant treatment after surgery, where treatment can continue for years and aims to lower recurrence risk. The firm’s global market model estimates roughly $27bn in combined peak sales across Roche’s giredestrant, AstraZeneca’s Etcamah/camizestrant, Lilly’s Inluriyo/imlunestrant and Menarini’s Orserdu/elacestrant in upfront and switch-adjuvant settings. The upfront setting is modeled as an approximately $18bn opportunity, with Roche dominant: $9.5bn of unadjusted global peak sales in intermediate-, medium- and high-risk patients and a further $6.1bn low-risk opportunity, probability-adjusted at 30% and assumed to launch in 2032. AstraZeneca’s CAMBRIA-2 is modeled at $2.5bn in global peak sales. The switch setting is estimated at roughly $10bn, supported by an approximately 100,000-patient US prevalence pool, although this pool is expected to decline to about 78,000 by 2035 as oral SERDs move earlier in treatment. For Lilly, Goldman Sachs views imlunestrant as underappreciated. Inluriyo generated roughly $75mn in 2Q26, its fourth quarter after launch, exceeding expectations in the approved second-line metastatic setting. More importantly, the firm introduces $6.4bn of unadjusted and $4.4bn of risk-adjusted peak sales for EMBER-4 in switch adjuvant disease, assigning a 70% probability of success. EMBER-4 enrolled roughly 8,000 patients and has an October 2027 primary-completion date; Goldman Sachs expects 2027 to remain the base case for a readout. The report believes tolerability could differentiate imlunestrant because Lilly and its management cite no notable cardiac or ocular signals to date, a potentially important factor for multi-year adjuvant treatment. Goldman Sachs raised its 2035 adjusted imlunestrant sales forecast to $5.1bn from $3.3bn and increased Lilly’s target price to $1,371 from $1,367. Roche’s giredestrant is viewed as the likely first mover in adjuvant disease. The lidERA trial reported an invasive disease-free survival hazard ratio of 0.70 against endocrine therapy and a 2.8% absolute three-year IDFS benefit, 92.4% versus 89.6%. Its November 30, 2026 PDUFA date is therefore a central catalyst. Goldman Sachs forecasts $15.2bn of non-risk-adjusted peak sales, including low-risk expansion, but expects early adoption to be steadier than market expectations as physicians await more mature survival data and insurers may resist use in lower-risk patients. Its FY27 and FY28 estimates are respectively 42% and 25% below Visible Alpha consensus. The report also flags uncertainty around giredestrant plus everolimus in ESR1 wild-type metastatic disease, while viewing the pionERA CDK4/6-inhibitor combination as more promising. For AstraZeneca, Goldman Sachs sees CAMBRIA-1 in 2H27 as the major adjuvant catalyst and raises its peak-sales forecast for that setting to $3.3bn from $1.2bn, with a 70% probability of success. CAMBRIA-2 contributes a modeled $2.5bn at 40% probability of success. The report forecasts $6.2bn of non-risk-adjusted Etcamah peak sales overall, broadly in line with Visible Alpha consensus. It raised SERENA-6 probability of success to 100% after FDA approval and reduced SERENA-4 probability of success to zero after the Phase 3 failure. Etcamah’s SERENA-6 data showed progression-free survival of 16.8 months versus 9.2 months for control, but overall survival was 41.2 versus 40.2 months at 30% maturity. Cardiac monitoring requirements, QT prolongation and bradycardia remain considerations, though Goldman Sachs does not expect clinically meaningful arrhythmia events from monotherapy in CAMBRIA-1. The report sets lidERA’s 0.70 IDFS hazard ratio as an important commercial benchmark for EMBER-4 and CAMBRIA-1, while acknowledging meaningful differences between immediate post-surgery treatment and switching after two to five years of endocrine therapy. Lilly considers a hazard ratio below 0.8 commercially meaningful, but Goldman Sachs is uncertain that delayed switch programs can materially outperform 0.70. It cites the modest prevalence of ESR1 mutations in the relevant setting and lidERA curve separation that slowed over time. Near-term attention should focus on Roche’s final label and launch dynamics, the 2027 EMBER-4 and CAMBRIA-1 results, safety and tolerability data, and the extent to which long-duration adjuvant pricing declines from the modeled $190,000 US net price at launch toward approximately $161,000 by 2035.

Analysis framework

Goldman Sachs combines a patient-funnel commercial model with trial-readout analysis, management discussions and key-opinion-leader feedback. It separates upfront and switch-adjuvant populations by recurrence risk, applies penetration, treatment-duration, pricing and probability-of-success assumptions, then compares modeled sales with Visible Alpha consensus forecasts and assesses clinical efficacy, safety and trial-design differences.

Methodology notes

• Industry AnalysisSupply-demand framework

  Patient-funnel market sizing for oral SERDs

  The report estimates addressable patient pools by recurrence risk, treatment setting and geography, then applies penetration, duration and pricing assumptions to derive sales potential.

• Industry AnalysisVolume-price decomposition

  Penetration, treatment duration and net-price assumptions

  Sales forecasts are built from expected patient use and multi-year treatment duration, with US annual net pricing modeled to decline from about $190,000 at launch toward roughly $161,000 by 2035.

• Valuation methodsDCF (Discounted Cash Flow)

  DCF valuation for Roche and AstraZeneca

  The report uses discounted cash flow as one component of the stated 50:50 DCF and P/E valuation blends for Roche and AstraZeneca.

• Valuation methodsP/E and PEG Valuation

  Earnings-multiple valuation

  Goldman Sachs applies stated P/E multiples to forecast EPS for Lilly, Roche and AstraZeneca when deriving price targets.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Eli Lilly & Co. / Inluriyo (imlunestrant)

  Covered company and oral-SERD participant; EMBER-4 is positioned as an underappreciated growth catalyst.

  Strengths

  Strong early metastatic launch, large 8,000-patient EMBER-4 trial, modeled tolerability differentiation and $6.4bn unadjusted adjuvant peak sales.

  Weaknesses

  Commercial outcome depends on an unreported EMBER-4 readout and later-line switch treatment may face efficacy constraints.

  Comparison

  Goldman Sachs models greater imlunestrant adjuvant potential than Visible Alpha consensus and sees broadly similar efficacy across leading oral SERDs.

  Risks

  Trial failure, weaker-than-expected data, competition, pricing pressure and execution risk.

• Roche / giredestrant

  Covered company and expected first mover in adjuvant oral SERDs.

  Strengths

  Positive lidERA data, first-mover advantage and potential expansion into low-risk populations.

  Weaknesses

  Goldman Sachs expects a gradual initial launch and sees uncertainty around the metastatic everolimus combination in ESR1 wild-type disease.

  Comparison

  Non-risk-adjusted $15.2bn peak-sales forecast is 55% above Visible Alpha consensus, but FY27/FY28 estimates are 42%/25% below consensus.

  Risks

  Label scope, reimbursement pushback, lower-than-expected early adoption and uncertainty around low-risk efficacy.

• AstraZeneca / Etcamah (camizestrant)

  Covered company and oral-SERD participant across metastatic and adjuvant settings.

  Strengths

  FDA approval in SERENA-6, modeled $3.3bn CAMBRIA-1 opportunity and differentiated CAMBRIA-2 combination strategy.

  Weaknesses

  SERENA-4 failed its primary endpoint; cardiac-monitoring and QT/bradycardia considerations may affect use.

  Comparison

  Overall $6.2bn non-risk-adjusted peak-sales estimate is broadly in line with Visible Alpha consensus.

  Risks

  Clinical failure, commercial execution, pricing, competition and patent exposure.

• Menarini / Orserdu (elacestrant)

  Private oral-SERD competitor in metastatic and switch-adjuvant treatment.

  Strengths

  First oral SERD approved in 2023 and quarterly revenue of roughly $166mn according to IQVIA data.

  Weaknesses

  Revenue trend appears flat following Lilly’s launch and the adjuvant ELEGANT trial has primary completion in August 2029.

  Comparison

  Goldman Sachs models $1.2bn of unadjusted peak sales for ELEGANT, below modeled Lilly and AstraZeneca switch-adjuvant opportunities.

  Risks

  Competitive pressure and uncertain clinical and commercial outcomes.

Key data

• Global adjuvant oral-SERD peak-sales opportunity~$27bnGoldman Sachs estimate across Roche, AstraZeneca, Lilly and Menarini; unrisked totals can sum to ~$29bn because of timing differences and rounding.
• US HR+/HER2-negative breast-cancer incidence~225k casesAnnual incidence cited by the report.
• Lilly imlunestrant adjuvant peak sales$6.4bn unadjusted; $4.4bn risk-adjustedEMBER-4 switch-adjuvant estimate using 70% probability of success.
• Roche giredestrant lidERA efficacyIDFS HR 0.70; 92.4% vs. 89.6% three-year IDFSCompared with endocrine therapy in medium- and high-risk adjuvant patients.
• AstraZeneca CAMBRIA-1 peak sales$3.3bnRaised from $1.2bn, with 70% probability of success.
• AstraZeneca SERENA-6 PFS16.8 months vs. 9.2 monthsEtcamah versus control; hazard ratio 0.45.
• Lilly Inluriyo quarterly revenue~$75mn in 2Q26Fourth quarter after launch and described as significantly above expectations.
• Switch-adjuvant US patient pool~100k currently; ~78k in 2035Expected to decline gradually as oral SERDs are used in upfront adjuvant treatment.

Impact & implications

The report sees adjuvant oral SERDs as a potential new growth cycle for large-cap pharmaceutical companies by restoring branded economics to an endocrine-treatment market long served by generics. The commercial outcome depends on efficacy relative to lidERA, timing of approvals, long-duration pricing, tolerability, payer access and the interaction between earlier-line adoption and later switch-adjuvant demand.

Risks

• Oral-SERD clinical trials may fail to demonstrate sufficient efficacy, particularly in delayed switch-adjuvant settings.
• Long-duration adjuvant use could lead to greater-than-expected net-price compression.
• Payer restrictions, physician caution and tolerability or monitoring requirements could slow uptake.
• Competition, patent exposure and weaker commercial execution could reduce modeled sales.

What to watch

• Roche’s November 30, 2026 lidERA PDUFA decision, final label scope and initial launch dynamics.
• Lilly EMBER-4 and AstraZeneca CAMBRIA-1 readouts expected in 2027, including IDFS/IBCFS efficacy and safety.
• Whether switch-adjuvant trials can approach or exceed lidERA’s 0.70 IDFS hazard-ratio benchmark.
• Cardiovascular, ocular and other tolerability data for competing oral SERDs.
• Evolution of US adjuvant net pricing and the pace at which upfront treatment reduces the switch-adjuvant patient pool.